Updates on BTK Inhibitors and Multiple Sclerosis Trials - Part 1

In part one of this series, Drs. Shuvro Roy, Jiwon Oh, and Amit Bar-Or discuss the results of the fenebrutinib trial and highlight the key takeaways that healthcare providers should be aware of. For more information, please read about the abstract that was presented at the 2026 AAN Annual Meeting . Read more about the Fenebrutinib Trial .